Results 131 to 140 of about 2,056 (145)

Stellungnahme von DOG, RG und BVA zur therapeutischen Anwendung von voretigene neparvovec (Luxturna™) in der Augenheilkunde[*]

Klinische Monatsblatter Fur Augenheilkunde, 2019
Berufsverband der Augenärzte Deutschlands E V
exaly   +2 more sources

Luxturna: FDA documents reveal the value of a costly gene therapy

Drug Discovery Today, 2019
Jonathan J Darrow
exaly  

Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy

Ophthalmology Retina, 2019

exaly  

Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease : Current Opinion in Ophthalmology

Current Opinion in Ophthalmology, 2020
Ramiro S Maldonado
exaly  

Luxturna® — erste Gentherapie in der Augenheilkunde : Ophthalmologie.

MMW Fortschritte Der Medizin, 2020
exaly  

Clinical and pharmacovigilance safety evaluation of LUXTURNA® (voretigene neparvovec-rzyl)

Cutaneous and Ocular Toxicology
Simon Kaja
exaly  

Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Annual Review of Virology, 2019
Allison Keeler-Klunk, Terence R Flotte
exaly  

Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version

Ophthalmologe, 2019
exaly  

Gene Therapy with Voretigene Neparvovec (Luxturna®)

Siegfried Priglinger
exaly  

Post-approval outcomes of voretigene neparvovec (Luxturna®) retinal gene therapy: A systematic review and meta-analysis.

Survey of Ophthalmology
Matthew P Simunovic, Antonia Rowson
exaly